EA011951B1 - Иммуноглобулины против антигена ерсам - Google Patents
Иммуноглобулины против антигена ерсам Download PDFInfo
- Publication number
- EA011951B1 EA011951B1 EA200601386A EA200601386A EA011951B1 EA 011951 B1 EA011951 B1 EA 011951B1 EA 200601386 A EA200601386 A EA 200601386A EA 200601386 A EA200601386 A EA 200601386A EA 011951 B1 EA011951 B1 EA 011951B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- immunoglobulin
- epcam
- human immunoglobulin
- serum
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 155
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 155
- 229940072221 immunoglobulins Drugs 0.000 title description 4
- 210000002966 serum Anatomy 0.000 claims abstract description 94
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims abstract description 71
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 44
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 230000029142 excretion Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000002314 small intestine cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 19
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 28
- 230000001225 therapeutic effect Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 206010018852 Haematoma Diseases 0.000 description 13
- 231100000331 toxic Toxicity 0.000 description 13
- 230000002588 toxic effect Effects 0.000 description 13
- 238000004088 simulation Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 11
- 230000035939 shock Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000003041 necroinflammatory effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 101100328105 Sus scrofa CLCA1 gene Proteins 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000037843 metastatic solid tumor Diseases 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010057212 Hepatitis viral infections Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000805 hepatocellular lesion Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/778,915 US20050180979A1 (en) | 2004-02-13 | 2004-02-13 | Anti-EpCAM immunoglobulins |
| PCT/EP2005/001307 WO2005080428A2 (en) | 2004-02-13 | 2005-02-09 | Anti-epcam immunoglobulins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200601386A1 EA200601386A1 (ru) | 2007-06-29 |
| EA011951B1 true EA011951B1 (ru) | 2009-06-30 |
Family
ID=34838270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200601386A EA011951B1 (ru) | 2004-02-13 | 2005-02-09 | Иммуноглобулины против антигена ерсам |
Country Status (23)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351919A1 (en) | 2003-01-24 | 2018-07-25 | University of Utah | Methods of predicting mortality risk by determining telomere length |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| WO2007090670A1 (en) | 2006-02-09 | 2007-08-16 | Micromet Ag | Treatment of metastatic breast cancer |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| ATE512988T1 (de) | 2007-04-04 | 2011-07-15 | Sigma Tau Ind Farmaceuti | Antikörper gegen epcam und anwendungen davon |
| EP2379747B1 (en) | 2008-12-22 | 2013-07-03 | University of Utah Research Foundation | Monochrome multiplex quantitative pcr |
| CN102844443B (zh) * | 2009-09-21 | 2014-08-06 | 保罗·沃尔菲什 | 用于甲状腺癌诊断和治疗的方法和组合物 |
| JP6163502B2 (ja) * | 2012-03-02 | 2017-07-12 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 |
| CN103409427B (zh) * | 2012-09-24 | 2016-05-18 | 厦门大学 | 上皮细胞粘附分子的核酸适体EpCAM C及其制备方法 |
| WO2014190138A2 (en) | 2013-05-22 | 2014-11-27 | Telomere Diagnostics, Inc. | Measures of short telomere abundance |
| CN103275226B (zh) * | 2013-06-09 | 2017-08-29 | 中国科学技术大学 | 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用 |
| PL3553087T3 (pl) * | 2014-01-08 | 2025-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Terapia celowana nowotworu złośliwego płuc |
| JP2018501799A (ja) | 2014-12-30 | 2018-01-25 | テロメア ダイアグノスティクス インコーポレイテッド | マルチプレックス定量的ｐｃｒ |
| DK3377103T4 (en) * | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN110035768A (zh) | 2016-07-26 | 2019-07-19 | 泰莎治疗私人有限公司 | 嵌合抗原受体 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| ATE200679T1 (de) * | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2446087C (en) * | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| US20030175268A1 (en) * | 2002-01-11 | 2003-09-18 | Saint-Remy Jean-Marie R. | Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome |
| CA2485691A1 (en) * | 2002-05-20 | 2003-12-04 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
-
2004
- 2004-02-13 US US10/778,915 patent/US20050180979A1/en not_active Abandoned
-
2005
- 2005-02-09 UA UAA200608985A patent/UA87128C2/ru unknown
- 2005-02-09 WO PCT/EP2005/001307 patent/WO2005080428A2/en not_active Ceased
- 2005-02-09 JP JP2006552536A patent/JP5220315B2/ja not_active Expired - Fee Related
- 2005-02-09 NZ NZ549125A patent/NZ549125A/en not_active IP Right Cessation
- 2005-02-09 CA CA2555694A patent/CA2555694C/en not_active Expired - Fee Related
- 2005-02-09 SI SI200530759T patent/SI1713830T1/sl unknown
- 2005-02-09 ES ES05707293T patent/ES2328159T3/es not_active Expired - Lifetime
- 2005-02-09 CN CN2005800099764A patent/CN1976951B/zh not_active Expired - Fee Related
- 2005-02-09 AT AT05707293T patent/ATE437186T1/de active
- 2005-02-09 PT PT05707293T patent/PT1713830E/pt unknown
- 2005-02-09 DK DK05707293T patent/DK1713830T3/da active
- 2005-02-09 US US10/589,450 patent/US20070274982A1/en not_active Abandoned
- 2005-02-09 PL PL05707293T patent/PL1713830T3/pl unknown
- 2005-02-09 DE DE602005015544T patent/DE602005015544D1/de not_active Expired - Lifetime
- 2005-02-09 BR BRPI0507660-9A patent/BRPI0507660A/pt not_active Application Discontinuation
- 2005-02-09 EP EP05707293A patent/EP1713830B1/en not_active Expired - Lifetime
- 2005-02-09 EA EA200601386A patent/EA011951B1/ru not_active IP Right Cessation
- 2005-02-09 AU AU2005215874A patent/AU2005215874B2/en not_active Ceased
- 2005-02-09 MX MXPA06008942A patent/MXPA06008942A/es active IP Right Grant
- 2005-02-09 EP EP09165284A patent/EP2107071A3/en not_active Withdrawn
- 2005-02-09 KR KR1020067016339A patent/KR101236224B1/ko not_active Expired - Fee Related
-
2006
- 2006-07-21 ZA ZA200606083A patent/ZA200606083B/en unknown
- 2006-07-25 IL IL177069A patent/IL177069A/en not_active IP Right Cessation
- 2006-09-13 NO NO20064136A patent/NO339364B1/no not_active IP Right Cessation
-
2012
- 2012-06-01 US US13/486,749 patent/US20120294873A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| LEWIS L.D.: "Technology evaluation: ING-1, XOMA", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 5, no. 4, 2003, pages 433-436, XP008052075, UK, cited in the application, the whole document * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12286480B2 (en) | Modulators of ROR1-ROR2 binding | |
| EA011951B1 (ru) | Иммуноглобулины против антигена ерсам | |
| Abdulkadyrov et al. | Sotatercept in patients with osteolytic lesions of multiple myeloma | |
| ES3037632T3 (en) | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia | |
| ZA200209815B (en) | Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents. | |
| O'Donnell et al. | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 | |
| US11648308B2 (en) | Methods, regimens, combinations and antagonists | |
| RU2009122344A (ru) | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 | |
| KR20240168479A (ko) | 건선 치료 방법 | |
| WO2019238713A2 (en) | Treatments etc | |
| JP2022044827A (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| Barete et al. | Is lirentelimab the ‘magic bullet’to fight pathological mast-cell activation in systemic mastocytosis? | |
| Schreiber et al. | T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4) | |
| Fasanmade et al. | T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease | |
| Hanauer et al. | T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial | |
| Hanauer et al. | T1130 Efficacy of Delayed-Release Oral Mesalamine in Patients Who Received Previous Ulcerative Colitis Treatment | |
| CN118946366A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| WO2006073586A8 (en) | Radiation dosimetry and blocking antibodies and methods and uses threfor in the treatment of cancer | |
| CN119300863A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| EA050171B1 (ru) | Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек | |
| Pfeiffer | Denosumab for bone loss due to prostate & breast cancer therapies continuing to show promise | |
| HK1250999B (en) | Modulators of ror1-ror2 binding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
| TC4A | Change in name of a patent proprietor in a eurasian patent | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |